BioHistory Moment: Iditarod Trail used to transport diphtheria serum to Nome.
In 1925, a life-or-death race to save the children of Nome from a diphtheria epidemic made an international hero of one
sled dog, and led to the creation of Alaska's Iditarod sled dog race. A diphtheria epidemic threatened
remotely located Nome, and air transportation was unavailable to transport serum from Anchorage nearly a thousand miles away.
The solution: A relay of dog teams transported serum on the Iditarod Trail from Nenana to Nome, and every village enroute
provided its best team and driver for the next leg continually moving the serum toward Nome. Gunnar Kaasen, a Norwegian musher,
drove the final two legs into Nome behind his lead dog Balto through a blizzard with 80 mph winds to deliver
300,000 units of diphtheria antitoxin to Dr. Curtis Welch, the only doctor in Nome.
The serum arrived in time, prevented the epidemic and saved hundreds of lives. The 20 mushers had covered nearly
700 miles in slightly more than 127 hours in temperatures of minus40° Fahrenheit below zero and strong winds.
The serum run received worldwide press coverage and the mushers received special gold medals and other recognition.
In 1926, a statue of Balto, the heroic lead dog, was erected in New York's Central Park.
 More...
Learn about Seattle's Life Science Incubator Facility
Seattle's Life Science Incubator Research facility was commissioned in 1988, and is a contemporary-designed building provided with
modern research systems. Four floors are specifically laboratory space, one floor is a fully equipped vivarium and one floor is clinical
space and management offices. The faciility is centrally located in close proximity to downtown Seattle, the University of Washington,
the Fred Hutchinson Cancer Research Center, and more.
Learn about this and other biotechnology, medical device and pharmaceutical facilities available for sale,
lease or sublease in Rhode Island, regionally or nationwide.
More...
(Advertising)
|
|
|
Industry News...
Free News Release Posting & Archiving Service
- GTC Biotherapeutics reports fourth quarter and fiscal year end 2009 financial results The total net loss for the fourth quarter was $1.7 million, or $0.09 per share, compared with $6.2 million, or $0.60 per share, for the fourth quarter of 2008. The total net loss for 2009 was $27.9 million, or $2.18 per share, compared to $22.7 million, or $2.31 per share, for 2008.
GTC Biotherapeutics, Inc. March 12, 2010
- Progenics to advance oral methylnaltrexone into late stage clinical development Progenics Pharmaceuticals announced that it plans to advance oral methylnaltrexone for the treatment of opioid-induced constipation into late stage clinical development and will commence a phase 2b/3 clinical trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010.
Progenics Pharmaceuticals, Inc. March 12, 2010
- FDA's Black Box Warning addressed by Genelex's PlavitestT The FDA added a new black box warning to Plavix, pointing out the importance of individual patient genetics in determining the effectiveness of Plavix treatment. The relabeling is in response to clinical research demonstrating that one-third of patients are in varying degrees of treatment failure.
Genelex Corporation March 12, 2010
- Pfizer discontinues a Phase 3 study of figitumumab Pfizer announced the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced NSCLC.
Pfizer Inc. March 11, 2010
- Two Phase 3 trials of sunitinib did not meet the primary endpoint Pfizer announced that two Phase 3 studies of Sutent(R) (sunitinib malate) in advanced breast cancer did not meet their primary endpoints.
Pfizer Inc. March 11, 2010
More... | Submit News Release | Advertising...
|
New Job Postings...
Free Job Posting Trial Offer
More... |
Job Advertising...
| About Job Postings...
|
New Facilities Available...
ATC clean room constructors...validation guaranteed!
More... |
Facility Advertising...
|
Upcoming Events...
 More... |
Submit Event |
Event Advertising...
|
|
Learn About Rhode Island's BioHistory
Why is there a life science industry in Rhode Island? Is the industry
growing? What do other states have?
Through Rhode Island BioHistory, you can learn about the scientists,
institutions, political leaders, and significant events that have shaped and are still shaping
the biotechnology, medical device and life science industry in Rhode Island.
More...
BioEvolution Posters
More...
March - National Colorectal Cancer Awareness Month
As a leading health organization for 25 years, the Prevent Cancer Foundation, the vision of Carolyn Aldigé, has
catapulted cancer prevention to prominence and provided more than $113 million in support of cancer prevention
and early detection research, education and community outreach programs across the country.
More...
BioFact
(1895) - A German company, Hochst am Main, sells Nitragin, the first commercially cultured Rhizobia isolated from root nodules.
It's a Small World
|
| |
Salmonella Typhimurium
| |
Science Quote
"The joy of discovery is certainly the liveliest that the mind of man can ever feel."
| - |
Claude Bernard, French physiologist
|
|
(1813-78)
|
|
